Update on the genetics of the idiopathic inflammatory myopathies
Ejaz A. Shamim, MD, MS, Lisa G. Rider, MD, and Frederick W. Miller, MD, PhD

A number of lines of investigation suggest that, as is likely the case for other autoimmune diseases, the idiopathic inflammatory myopathies (IIM) develop as a result of specific environmental exposures in genetically susceptible individuals. Current data imply that multiple genes are involved in the etiology of these complex disorders. Targeted gene studies and whole genome approaches have begun to identify several genetic risk factors for autoimmune diseases, but the rarity and heterogeneity of the IIM have limited our knowledge of their associated genes. Current findings suggest that human leukocyte antigen (HLA) genes on chromosome 6, particularly HLA DRB1*0301 and the linked allele DQA1*0501, have the strongest associations with all clinical forms of IIM in white patients. Different HLA alleles, however, may confer risk or protection for myositis in distinct ethnic, serologic, and environmental exposure groups. Non-HLA genetic risk factors, which have been documented for other autoimmune diseases, are now being identified for the IIM. These include polymorphic genes encoding immunoglobulin heavy chains (defined by serologic markers known as Gm allotypes), cytokines and their receptors, and certain proteins that accumulate in the myocyte vacuoles of inclusion body myositis patients. Selected allelic polymorphisms of interleukin-1 receptor antagonist variable number tandem repeats and genes for tumor necrosis factor alpha and interleukin-1 alpha also have recently been associated with IIM. The pathogenic bases for the differences among the many clinically, pathologically and immunologically defined syndromes known as the IIM will be elucidated through a better understanding of the multiple genes that define risks for their development, as well as through investigations of gene-gene and gene-environment interactions. Curr Opin Rheumatol 2000, 12:482–491 © 2000 Lippincott Williams & Wilkins, Inc.

The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare systemic connective tissue diseases that are defined by the presence of acquired muscle weakness and chronic inflammation of unknown cause. Polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) are the most common clinical forms of these diseases and they are likely increasing in prevalence [1]. The frequency of the clinical and serologic subsets, as well as the risk factors for developing IIM, may differ among distinct ethnic groups in geographically isolated parts of the world [2,3•,4,5].

The pathogeneses of the IIM remain unclear, although evidence from family, cohort, and candidate gene studies suggest a genetic component and that many different genes are likely necessary for the development of these diseases [6•]. Current findings imply, however, that genetic factors themselves are not adequate for the development of disease. Rather, in genetically predisposed individuals, disease probably develops only after exposure to critical environmental triggers [7,8]. In this article, we summarize the current understanding of the genetics of the IIM. The genetics of the familial non-inflammatory forms of the inclusion body myopathies, which are not considered IIM, will not be covered here, but have been recently reviewed elsewhere [9].

Approaches to the study of genetic risk factors for autoimmune disease
Several approaches have been used to assess the role of genetics in the development of autoimmune diseases and some of these have been applied to the IIM (Table 1) [6•]. The oldest is the simple description of the same autoimmune disease occurring in multiple members of a single family. These multicase families with autoimmunity suggest a genetic etiology and/or shared environmental factors in the pathogenesis of these diseases. In recent decades, familial associations of several autoimmune diseases, including IIM, have been reported. To date, a total of 34 families in which two or more members have
Table 1. Approaches to assess the genetics of autoimmune diseases

| Approach | Examples in IIM | Examples in other autoimmune diseases |
|----------|-----------------|----------------------------------------|
| Reports of multicase families with the same autoimmune disease | 34 families reported with ≥ two cases of PM, DM, IBM, amyopathic DM, or orbital myositis [8••,24,25] | IDDM: Mennonite kindred [64] |
| Studies of concordance rates in monozygotic twins vs dizygotic twins | No studies to date | RA: Four generations of women in one family with RA [65] |
| Genetic investigations of multicase families with the same autoimmune diseases | HLA DRB1*0301 and homozygosity of HLA DQA1 are risk factors for familial IIM [29] | IDDM: 53% concordance in MZ twins vs 11% in DZ twins [66] |
| Candidate gene studies | MHC genes primarily investigated; HLA DRB1*0301 and DQA1*0501 are major risk factors (see Tables 3,4) | RA: 15% concordance in MZ twins vs 4% in DZ twins [67] |
| Whole genome scans | No studies to date | Preliminary genome scans performed for SLE, RA, JRA, and AS [71] |

AS, ankylosing spondylitis; DM, dermatomyositis; DZ, dizygotic; HLA, human leukocyte antigen; IBM, inclusion body myositis; IDDM, insulin-dependent diabetes mellitus (type 1); IIM, idiopathic inflammatory myopathy; IL, interleukin; JRA, juvenile RA; MHC, major histocompatibility complex; MS, multiple sclerosis; MZ, monozygotic twins; PM, polymyositis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

In addition to these shared autoimmunity predisposing genes, however, other genes and/or environmental exposures likely determine which specific autoimmune disease an individual will develop [6••,16].

Candidate gene studies, using cohort comparisons between affected patients and racially- and geographically-matched healthy controls to assess potential disease-associated genes based upon suspected pathogenic mechanisms, have shown that the major histocompatibility complex (MHC) region on chromosome 6 has the strongest association with most immune-mediated diseases. In some cases, these risk factors have also been confirmed by family-based methodologies, such as transmission disequilibrium testing, in which unaffected parents are used as controls [17]. Through candidate gene approaches in cohort-based studies, other polymorphic genetic loci, including genes encoding cytokines and their receptors, T-cell receptors, immunoglobulins, Fc receptors, and autoantigens have been identified as risk factors for various autoimmune diseases, but their statistical associations with disease are weaker than those of the MHC [18,19]. The data overall, however, suggest that many of these other genetic loci are involved as secondary risk factors [16,20••,21•]. Candidate gene approaches, which constitute the primary data that have been used to identify immunogenetic risk factors for the IIM, are detailed below.

The most recent genetic approaches have involved whole genome scans in multiple-case families with single autoimmune diseases (Table 1), or in animal models of inherited autoimmune diseases. These studies have assessed microsatellite or other markers on all chromosomes for linkage to particular phenotypes (reviewed in [6••]), and suggest that perhaps several...
dozen genes may play a role in the development of many autoimmune disorders [16]. The rarity of multicase families with IIM and the lack of an appropriate animal model have not allowed such genome-wide scans to be performed in IIM.

### Evidence for familial idiopathic inflammatory myopathy and familial autoimmunity in pedigrees of idiopathic inflammatory myopathy probands

Although the initial clinical descriptions of myositis occurred in the 1800s [22], the first report of myositis affecting multiple family members was not published until 1953, when Wedgewood noted juvenile DM in twins with disease onset within 1 year [23]. Over the next several decades, similar aggregations in first-degree family members of other clinical forms of myositis, including PM, DM, IBM, orbital myositis, and amyopathic DM [6•,24,25], as well as IIM among more distant relatives [6•] were described (Table 2). In 1991, a report of concurrent onset of PM in four family members living in the same rural location emphasized both the likely genetic and environmental aspects of this disease [26]. In the subsequent year, a kindred study implied a possible autosomal dominant inheritance pattern for some types of IBM [27]. To date, a total of 34 families in which two or more members have IIM have been reported [6•,24,25].

A study of all forms of familial IIM compared a large number of multicase IIM families (36 IIM patients with PM, DM, or IBM from 16 unrelated families in which two or more family members have an IIM) to sporadic IIM (181 unrelated cases) with regard to clinical features, serology, and immunogenetic risk factors [11]. Of interest, in most of the familial IIM patients, the same clinical group was shared among all members of a given family who developed myositis. The sporadic IIM group had a higher frequency of myositis-specific autoantibodies (MSAs) compared with familial IIM, and after adjustment for the clinical associations with the MSAs, no significant clinical differences were observed between the familial and sporadic IIM groups. HLA DRB1*0301 was a risk factor for familial IIM, as is the case for sporadic IIM; however, homozygosity of DQA1 was an additional unique risk factor for familial forms of myositis [28].

In 1997, Pachman et al. [29] assessed histories for autoimmune diseases in family members of juvenile rheumatoid arthritis (JRA), juvenile DM patients with sporadic disease, and geographically matched healthy controls. They noted that pedigrees of children with JRA had a significantly higher frequency of rheumatoid arthritis and pernicious anemia than controls, but this was not observed in the juvenile DM families.

### Table 2. Highlights of the chronology of published reports of multicase idiopathic inflammatory myopathy failure

| Study                        | Comments                                                                 |
|------------------------------|--------------------------------------------------------------------------|
| Wedgewood et al. [23], 1953  | First report of familial IIM; juvenile DM in twins                       |
| Winkler [72], 1956           | First report of non-twin familial IIM; siblings with juvenile DM         |
| Lambie and Duff [73], 1963   | First report of juvenile DM in cousins                                    |
| Hennekam et al. [74], 1998   | First report of juvenile DM cousins living in different towns            |
| Harati et al. [75], 1991     | First report of four family members in same household developing PM, with possible association with local rodents |
| Massa et al. [76], 1991      | First report of IBM in siblings                                           |
| Neville et al. [27], 1992    | First report of a large kindred with IBM, suggesting an autosomal dominant inheritance pattern |
| Rider et al. [11], 1998      | Largest study of familial IIM (16 multicase families); new findings included: a lower frequency of MSAs, but no difference in clinical features; DRB1*0301 is a shared risk factor with sporadic IBM, but homozygosity of the DQA1 allele is a unique risk factor for familial IIM |
| Ginn et al. [14], 1998       | First report of increased frequency of other autoimmune diseases in pedigrees of IIM patients |
| Plamondon et al. [25], 1999  | First report of juvenile DM and amyopathic DM in siblings who share DQA1*0501 |
| Maurer and Zierz [24], 1999  | Report of four family members with orbital myositis                      |

DM, dermatomyositis; IBM, inclusion body myositis; IIM, idiopathic inflammatory myopathy; MSAs, myositis-specific autoantibodies; PM, polymyositis.

The first study to assess the frequency of all autoimmune diseases in families of sporadic IIM patients was published in 1998 [14]. This prospective case-controlled investigation demonstrated that the prevalence of autoimmune disease was significantly higher (21.9%) in the 151 first-degree relatives of 21 IIM patients compared with that in 143 first-degree relatives of 21 age-, gender- and race-matched probands without evidence of an autoimmune disease (4.9%) [14]. As expected, these pedigrees also demonstrated a female predominance for autoimmunity, an increase in frequency of autoimmune diseases with increasing age, and, through genetic modeling, that autoimmune diseases in these families likely have a polygenic mode of inheritance.

### Evidence that HLA alleles are risk factors for idiopathic inflammatory myopathy

Although hereditary aspects of myositis were recognized half a century ago, only in the last two decades have laboratory approaches been applied in an attempt to identify the specific genes responsible for the development of the IIM (Tables 3,4). Of the many polymorphic genetic loci that may be risk factors for myositis and other autoimmune diseases, the HLA region on chromo-
some 6 appears to encompass the strongest risk factor. As with other complex disorders [21•], many non-HLA polymorphic loci are also likely to be involved in the pathogenesis of the IIM (Table 5).

HLA B8, an MHC class I allele defined by serologic methods, was the first genetic marker associated with IIM in a study of patients with juvenile DM [30]. As serologic HLA testing evolved into molecular techniques and larger numbers of patients were studied, this initial finding was discovered to be more likely due to linkage disequilibrium with HLA class II genes, because HLA A1;B8;Cw7;DRB1*0301;DQA1*0501;C4A*Q0 constitutes a common extended haplotype in white populations [30,31]. HLA DRB1*0301 and DQA1*0501 have now been determined to be risk factors for all the major clinical forms of sporadic and familial IIM in both white adults and children in the US and Europe [2,30–33]. Some of these results from cohort-control studies have also been confirmed by transmission disequilibrium testing analysis of sporadic juvenile DM families [31]. Recently, in a small, single-center study, other HLA Class II alleles, DMA*0103 and DMB*0102, have been identified as possible risk factors for juvenile DM in white patients [34••].

Small studies of ethnic minorities in the US have shown HLA DQA1*0501, but not DRB1*0301, to be a risk factor for adult IIM and juvenile DM in black patients [32,35]. HLA DQA1*0501 has also been found to be increased in Hispanic juvenile DM patients compared with controls [35], but not in Hispanic adult IIM subjects [32]. In other ethnic groups living outside the US, different genes appear to be risk factors for the IIM. In Korean IIM patients, for example, despite their clinical and serologic similarity to US white IIM subjects, no HLA allele has been identified as a risk factor. HLA DRB1*14, however, is a unique protective factor for IIM.

Table 3. Human leukocyte antigen association with idiopathic inflammatory myopathy clinical groups

| Clinical group (race)                  | Associated alleles† | Comments† [references] |
|---------------------------------------|---------------------|------------------------|
| IIM, PM, DM (white)                   | DRB1*0301, DQA1*0501, DQB1*0201 | OR = 2.3 – 11.2 (2.4 – 19.7); P = 0.02 – 0.17 [2,3,11,32] |
|                                       | °EYSTS, DRB1 HVR motif | OR = 3.1 (1.8–5.4); Pc = 4.7 × 10⁻⁴ [3] |
|                                       | DR3, Drw52           | P < 0.001 [33] |
|                                       | CA4*Q0              | RR = 2.7, P = 0.08 [77] |
|                                       | DR3 (possible B8)   | P = 0.003, Pc = 0.02 (for B8: P = 0.005, Pc = NS) [78] |
|                                       | DRB1*0201 and *0501 (protective factor) | P < 0.001 [2] |
|                                       | DR4 (protective factor) | Pc = 0.04 [78] |
| Familial IIM (mixed)                  | DQA1 homzygosyogy   | OR = 4.2 (1.7–10.2), P = 0.002 [11] |
| IBM (white)                           | Locus between DR and C4 | Statistics not available [20] |
|                                       | DRB1*0301, DRB3*0101, DQB1*0201 | P < 0.01 [79] |
|                                       | B8, CA4*QQ, DR3, Drw52 | P < 0.01 [50] |
|                                       | DR3 (possible DR1, DR6, DRQ) | Statistics not available [33] |
| Juvenile DM (white)                   | DMA*0103; DMB*0102  | RR = 5.7, Pc = 0.0016, RR = 8, P = 0.036, Pc = 0.19 [34] |
|                                       | DQA1*0501           | TDT analysis, P < 0.01 × 10⁻⁴ [35,80] |
|                                       | DQA1*0501, DR3       | P = 0.024 [31,81] |
|                                       | C4A*Q0              | P < 0.01 [32] |
|                                       | B8                  | RR = 2.8; Pc < 0.01 [30] |
| IIM, PM (black)                       | DQA1*0501, and/or DQA1*0401 | OR = 2.7, P = 0.01, Pc = 0.09 [32] |
|                                       | CA4*Q0              | RR = 1.8, P = NS [77] |
|                                       | B7; Drw6            | P = 0.02, P = NS, P = 0.005, P = 0.04 [78] |
| Juvenile DM (black)                   | DQA1*0501           | P < 9 × 10⁻⁴ [35] |
| IIM, PM, DM (Hispanic)                | No HLA association detected. | [32] |
| Juvenile DM (Hispanic)                | DQA1*0501           | P < 9 × 10⁻⁴ [35] |
| IIM (Meso-American)                   | DQA1*0101 (protective factor) | P < 0.001, Pc = 0.006 [4] |
| IIM (Japanese)                        | DR3                 | P < 0.05 [81] |
| IIM (Korean)                          | No HLA association detected. | [3] |
| IIM (Japanese)                        | B7                  | OR = 3.4 (1.1 – 10.7); P = 0.02, P = NS [5] |
|                                       | DQA1*0501 (protective factor) | OR = 0.32 (0.09 – 1.0), P = 0.04, P = NS [5] |
|                                       | DQB1*0301 (protective factor) | OR = 0.36 (0.15 – 0.88), P = 0.02, P = NS [5] |
| PM (Japanese)                         | CW3 (compared with DM) | OR = 3.0 (1.1 – 8.8), P = 0.02, P = NS [5] |
| DM (Japanese)                         | DRB1*08             | OR = 2.3, P = 0.004 [5] |
| Overlap (Japanese)                    | DR 59               | OR = 14.3; P = 0.01, P = NS [5] |
|                                       | B7                  | OR = 8.1 (1.93–34.0), P = 0.005, P = NS [5] |
|                                       | DRB1*0101           | OR = 3.5 (1.03–3.67); P = 0.04, P = NS [5] |

†Although the data currently suggest stronger associations with the HLA Class II alleles than with the HLA class I alleles, there has not been a formal comparison of the strength of association of these linked alleles on the common white haplotype HLA A1;B8;Cw7;DRB1*0301;DQA1*0501;DQB1*0201;CA4*Q0. °95% confidence interval is enclosed in parentheses when available. §P value calculated from published data. ¶Data for all races combined.

DM, dermatomyositis; IBM, inclusion body myositis; HLA, human leukocyte antigen; HVR, hypervariable region, IIM, idiopathic inflammatory myopathy; NS, not significant; OR, odds ratio; Pc, P value corrected for multiple comparisons; RR, relative risk; TDT, transmission disequilibrium test.
myositis in Korean patients without MSAs [3•]. In Japanese patients, HLA B7 has been reported to be a genetic risk factor for the development of IIM, and DQA1*0501 is, surprisingly, a protective factor [5], whereas in Meso-American patients HLA DQA1*0501 may be a protective factor [4].

Myositis-specific autoantibodies appear to define syndromes with associated clinical features, prognoses, and responses to treatment [33] (see the review by Targoff in this issue [pp 475–481]). As is the case in other autoimmune disorders, different HLA class II alleles serve as risk factors for the development of different autoantibodies (Table 4). For example, antisynthetase autoantibodies are associated with DRB1*0301 (OR = 9.6) and DQA1*0501 (OR = 5.8) in white patients [32]. In black and Mexican American patients, HLA DQA1*0501 and/or DQA1*0401 are increased in frequency in patients with anti-Jo-1 autoantibodies compared with controls, but DRB1*0301 was not identified as a risk factor (although this study is limited in power) [32]. In contrast, patients with other autoantibodies have other immunogenetic risk factors. Anti-Mi-2 autoantibodies are associated with HLA DR7 (OR = 84) and the linked allele HLA DQA1*0201 (OR = 20) in white patients [36], whereas patients with anti-signal

### Table 4. Human leukocyte antigen associations with idiopathic inflammatory myopathy serologic groups

| Serologic group (race) | Associated alleles | Comments [reference] |
|------------------------|-------------------|----------------------|
| MSA positive (white)†  | DRB1*0103, DQA1*0501, DR3, DR7, DRw53 | OR = 4.4, P = 0.02 [32] |
| Anti-Jo-1 (white)      | DRB1*0103, DQA1*0501, DR3, DR7, DRw53 | OR = 9.8, P = 3 x 10^-6; OR = 8.3, P = 4 x 10^-4 [32] |
| Anti-Jo-1 (black, Hispanic, and white) | DQA1*0501 and/or DQA1*0401, DRB1*07 | OR = 7.4, P = 1 x 10^-5 [32] |
| Anti-Mi-2 (white)      | DRB1*0103, DQA1*0501, DR3, DR7, DRw53 | OR = 5.8, P = 1 x 10^-5 [32] |
| Anti-SRP (mixed)       | DRB1*0103, DQA1*0501, DR3, DR7, DRw53 | OR = 22 (4.6–105.6), P < 1 x 10^-4 [36] |
| Anti-PM/ScI (white)    | DRB1*0103, DQA1*0501, DR3, DR7, DRw53 | OR = 20 (4.4–93.4), P < 1 x 10^-4 [36] |
| Anti-Ku (white)        | DRB1*0103, DQA1*0501, DR3, DR7, DRw53 | OR = 25 (6.2–99.4), P < 1 x 10^-4 [36] |

### Table 5. Non-HLA polymorphic genetic marker associations with the idiopathic inflammatory myopathies

| IIM group (race) | Gene/chromosome/allele | Comments [reference] |
|------------------|------------------------|----------------------|
| Juvenile IIM (white) | IL1RN/2/IL1RN A1, IL1RN/2/IL1RN A3 | OR = 2.5, 95% CI = 1.1 - 5.8; Pc = 0.037 [44] |
| Juvenile IIM (black) | TNF-α 308A/B/TNF-α 238B | A risk factor for juvenile DM in white patients, increased in frequency in patients with a chronic disease course (P = 0.001), calcinosis (P = 0.017) [49,57] |
| Juvenile DM (white) | GM1/14/Gm21 allotype | OR = 0.3, 95% CI = 0.13–0.7 [3] |
| IIM (Korean)      | DRB1*0103/DQA1*0501, 3DR7, 3DRw53 | No GM phenotype or allotype is a risk or protective factor in white patients |
| Juvenile IIM (white) | TNF-α 238B/TNF-α 308A | OR = 5.2, Pc ≤ 0.0002; in linkage disequilibrium with DRB1*0301 [45] |
| IBM (white)       | PRNP/PRNP A/M | OR = 0.23 [50,87] |
| Juvenile IIM (white) | TNF-α 238B/TNF-α 308A | OR = 5.2, Pc < 0.002; in linkage disequilibrium with DRB1*0301 [45] |
| Juvenile IIM (white) | IL1-α/IL1-α | RR = 0.25, Pc < 0.003 (a protective factor) [45] |
| Juvenile IIM (white) | IL1-α/IL1-α | RR = 4, Pc = 0.003 (heterozygosity is a risk factor) [45] |
| IBM (white)       | AP0E/19 or 4 | Heterozygosity seen in 5/5 patients, but is not significant |

All studies unconfirmed to date. †Methionine homozygosity.

AP0E, apolipoprotein E allele; DM, dermatomyositis; IBM, inclusion body myositis; IIM, idiopathic inflammatory myopathy; IL-1α, interleukin-1 alpha; IL1RN, gene encoding interleukin-1 receptor antagonist; OR, odds ratio; Pc, P value corrected for multiple comparisons; OR, odds ratio; PRNP, prion protein gene allele; RR, relative risk; TNF-α, tumor necrosis factor alpha; VNTR, variable number tandem repeat.
recognition particle autoantibodies have an increased frequency of HLA DR5 and DQA1*0301 compared with normal controls [33]. White IIM subjects with anti-PM-Scl and anti-Ku autoantibodies have higher frequencies of HLA DRB1*0301 and DQA1*0501 alleles compared with controls (Table 4). Genetic studies of other IIM serologic groups have not yet been reported.

Though gene-environment interactions are inherently difficult to study in rare diseases, certain HLA class II alleles may be risk factors for IIM associated with particular environmental exposures. Furthermore, the genetic risk factors for the development of myositis after certain exposures may differ among distinct racial groups, as may be the case with D-penicillamine [37]. In white patients from the US and in patients from the Indian subcontinent, DR2 appears to be associated with development of myositis after D-penicillamine exposure [37,38]. In the later group, DQW1 also appears to be a risk factor. In white subjects in Australia, however, HLA DR4, B18, and B35 were associated with the development of myositis after D-penicillamine exposure. A small retrospective comparison study noted that white women who developed myositis after silicone breast implantation had a higher frequency of HLA DQA1*0102, compared with race-matched controls or white IIM patients without implants [28]. These studies, though limited in power by their size, suggest the importance of both genetic and environmental components in the pathogenesis of myositis in some individuals.

**Evidence that non-HLA alleles are risk factors for idiopathic inflammatory myositis**

Non-HLA loci, which have been defined as likely risk factors for other autoimmune diseases [16,18,39], may also play a role in the pathogenesis of the IIM [3•,39–41] (Table 5). Risk factors for other autoimmune diseases include genes encoding cytokines and their receptors, immunoglobulins, and loci containing a large number of genes whose functions remain unclear [3•,39]. To date, few such loci have been studied in the IIM, and the published associations are preliminary and require confirmation. The likelihood that the non-HLA genes will have much weaker associations with disease than the HLA genes suggests that very large populations of patients and race-matched controls will be needed to identify most of the polygenic risk factors for IIM.

Gm allotypes are serologic markers on IgG heavy chains encoded on chromosome 14 and thought to be associated with the regulation of immunoglobulin responses to certain exposures. They have been defined as markers for a number of autoimmune, infectious and malignant diseases [41]. Gm 21 has recently been shown to be a protective factor for IIM in Koreans, but not in white patients in the US [3•].

The gene encoding the interleukin-1 receptor antagonist (IL-1RN), located on chromosome 2, has five allelic polymorphisms (A1–A5) of an 86 base pair variable number tandem repeat in intron 2 which represent two to six copies of the repeat sequence [42,43]. The specific allele IL-1RN A1, which is defined by four copies of the variable number tandem repeat, has been shown to be a risk factor for juvenile IIM in white patients (OR = 2.5) [44••]. This allele is not increased in black patients, but IL-1RN A3, representing five repeats, is a possible risk factor in this ethnic group [44••]. In contrast to studies of other autoimmune diseases, the IL-1RN A2 has not been identified as a severity factor for juvenile IIM [44••]. A second polymorphic gene on chromosome 2, IL-1α 1,2 (defined by a single G to T substitution in exon 5), has also been identified as a possible risk factor in juvenile IIM in white patients [45]. In contrast, no alleles of the polymorphic IL-1β gene have been identified as risk or protective factors in white juvenile IIM patients.

Tumor necrosis factor alpha (TNF-α), encoded within the MHC, plays a number of important roles in the regulation of normal and pathologic immune responses. The promoter region of TNF-α has two polymorphic sites at nucleotide positions -238 and -308 (referred to as TNF1 and TNF2 at each site). At both nucleotide positions, TNF2 is distinguished from TNF1 by a G to A substitution. Thus, the two alleles at position -238 are named TNF1 (-238G) and TNF2 (-238A), and the two alleles at -308 are referred to as TNF1 (-308G) and TNF2 (-308A). The TNF2 (-238A) allele appears to be a possible risk factor for juvenile IIM in white patients, although this finding may be due to its linkage with DRB1*0301 [45]. The other polymorphism of the TNF-α gene, resulting from a G to A substitution at position -308, appears to be a risk factor for juvenile DM in white patients [45]. Homozygosity of TNF (-308A) confers a high risk of death or severe neurologic involvement in patients with cerebral malaria [46]. This allele may also be a risk factor for systemic lupus erythematosus and several other autoimmune diseases [43,47]. Furthermore, in patients with juvenile DM, TNF2 (-308A), which is associated with higher levels of TNF-α after in vitro stimulation of peripheral lymphocytes, is increased in white patients with calcinosis, a chronic disease course, and capillary occlusion on biopsy, suggesting the -308 TNF-α allele may be a severity factor [45,48,49•].

HLA DRB1*0301 appears to be an important risk factor for sporadic inflammatory forms of IBM, but not for the hereditary noninflammatory forms of the inclusion body myopathies [50]. Nonetheless, recent findings imply that...
non-HLA genes may also play a role in the pathogenesis of IBM, the most common form of IIM in the elderly. IBM is characterized on muscle biopsy by intracellular inclusions containing many components. The prion protein has been found to be one constituent of these intracellular inclusions and is encoded by a polymorphic gene, which results in a protein containing either a methionine or valine at codon 129 [51]. An unconfirmed study has recently suggested that homozygosity at codon 129 (encoding methionine) of the prion gene may be a predisposing factor for IBM [52••]. This is of interest because overexpression of the prion gene in transgenic mice leads to a pathologic state similar to IBM [53]. An additional protein component of the intracellular rimmed vacuoles of IBM is apolipoprotein E (apoE), which is also found in the brain plaques of patients with Alzheimer disease [54]. The major known function of apoE is the transport of lipoproteins in the blood. In humans, 3 major isoforms are found: E2, E3 and E4. The single amino acid differences between the apolipoprotein isoforms confer differing affinities for apoE receptors as well as for lipoprotein subtypes. The frequency of one variant of the apoE gene, the APO E ε4 allele, is increased in patients with IBM compared with the general population. This unconfirmed result in a small population suggests that the APO E ε4 allele may be a predisposing factor for the development of IBM [55].

**Future approaches for the investigation of genetic risk factors in the idiopathic inflammatory myopathies**

Many challenges lie ahead in the further definition of genetic risk factors for the IIMs. A common difficulty faced by all researchers assessing the genetic basis of autoimmune diseases is the identification of genes of relatively small effect size, against a background of substantial genetic and environmental variation, using populations often of inadequate size. In addition, specific challenges in identifying genetic risk factors for the myositis syndromes include the rarity and heterogeneity of the IIM, the apparent differences in genetics among the various clinical, serologic, and ethnic groups, and the likely gene-gene interactions that define these diseases. It may be that certain alleles of many polymorphic, physically unlinked genes have been evolutionarily selected to work together as functional units to optimize immune responses to infections and other environmental exposures. If this is the case, then it is possible that some combinations of these polymorphisms may result in abnormal immune responses in certain environments, which could lead to autoimmune disease [56].

As is the case for many other autoimmune diseases, gene-environment interactions also seem to play an important role in the initiation of the IIM. Thus, multidisciplinary approaches which explore the interaction of genetic and environmental factors by integrating a variety of study designs and take into account the advantages and disadvantages of each, should be considered in future studies [8,44,57,58]. Because it is likely that the heterogeneity of the myositis syndromes reflects varied pathogenic mechanisms in different individuals, it may also be useful to study genotypes in groups of patients classified in new ways. These approaches could include assessing novel IIM phenotypes defined by (1) unique clusters of specific signs, symptoms, and laboratory abnormalities; (2) common patterns of target tissue gene expression using cDNA microarray technology; or (3) different responses to immunomodulating agents.

A major limitation has been the relatively small numbers of subjects within each of the subgroups available for investigation. To address this problem, national and international collaborative efforts have been initiated, and need to be extended, to develop serum and DNA repositories on large populations of well-characterized subjects. This will also allow expansion of these studies to other clinical, serologic and environmental exposure subgroups of myositis that have not yet been studied.

In addition to collaborative efforts to increase population sizes, new technologies and epidemiologic approaches should enhance these efforts [17,59–63]. The human genome project, and its resultant high resolution mapping of MHC and non-MHC regions, may allow an understanding of the true genetic risk factors, rather than those that may only be linked to the true risks. The expanding fields of gene chip and microarray technologies also hold special promise in understanding the pathogeneses of complex disease traits like myositis, inasmuch as the interaction of many different polymorphic gene products can be rapidly assessed in large populations using these methodologies.

In summary, our understanding of the genetics of IIM is in an early stage of development. Many of the current findings in this field are preliminary observations, limited by small samples and weak effect sizes, and should not be considered definitive. The early indications of heterogeneity of genetic risk and protective factors among different serologic and ethnic groups, as well as possible gene-environment interactions, suggest that enhanced understanding in this area should have important diagnostic, therapeutic and preventative implications for improving outcomes of myositis patients in the future.

**Acknowledgments**

The authors thank Drs. Steve Bauer, Syed R. Husain, Terrance P. O’Hanlon, and Ms. Uzma Haq for useful comments and assistance during the preparation of this manuscript.

The opinions expressed in this paper are those of the authors and not necessarily those of the Center for Biologics Evaluation and Research or the Food and Drug Administration.
References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:
• Of special interest
•• Of outstanding interest

1. Oddis CV, Conte CG, Steen VD, et al.: Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol 1990, 17:1329–1334.

2. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al.: Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997, 40:1257–1266.

3. Rider LG, Shamim E, Okada S, et al.: Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999, 42:1285–1290.

This is the first study to assess the genetic, serologic, and clinical features of IIM patients from different geographically isolated ethnic groups. Though the serologic and clinical features were similar in 50 Korean and 151 US white IIM patients, genetic differences were noted. No HLA risk factors were seen in the Korean cohort; however, Gm 21 was a protective factor. DRB1*14 was also a protective factor, but only in those patients who did not have MSAs. This suggests that many genes and environmental triggers may play a role in the pathogenesis of IIM.

4. Shamim EA, Rider LG, O’Hanlon TP, et al.: Clinical serologic and genetic differences between US caucasian and meso-Americans with idiopathic inflammatory myopathy (IIM) [abstract]. Arthritis Rheum 1999, 42:5403.

5. Furuya T, Hakoda M, Higami K, et al.: Association of HLA class I and class II alleles with myositis in Japanese patients. J Rheumatol 1998, 25:1109–1114.

A review of familial autoimmunity and a chronological listing of the 33 reported cases of familial IIM. Familial autoimmunity is described within the context of a new paradigm—the concept of currently defined disease being composed of constituent elemental disorders, each of which is defined by unique signs, symptoms, and laboratory abnormalities that arise from a distinct pathogenic process.

6. Shamim E, Miller FW: Familial autoimmunity and the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000, 2:201–211.

7. Luppi P, Rosselli MR, Faas S, et al.: Genetic background and environment contribute synergistically to the onset of autoimmune diseases. J Mol Med 1995, 73:381–393.

8. Miller FW: Genetics of environmentally-associated rheumatic disease. In Rheumatic diseases and the environment. Edited by Kaufman LD, Varga J. New York: Chapman Hall; 1998:33–45.

9. Argov Z, Eisenberg I, Mitrani-Rosenbaum S: Genetics of inclusion body myopathies. Curr Opin Rheumatol 1998, 10:543–547.

10. Huang DF, Sminovitch KA, Liu XY, et al.: Population and family studies of three disease-related polymorphic genes in systemic lupus erythematosus. J Clin Invest 1995, 95:1766–1772.

11. Rider LG, Garley RC, Pardey JP, et al.: Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 1998, 41:710–719.

12. Ramenghi U, Bonisso N, Migliaretti G, et al.: Deficiency of the fas apoptotic pathway without fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood 2000, 95:3176–3182.

13. Pastore MR, Bazzigaluppi E, Bonfanti R, et al.: Two-step islet autoimmune screening for risk assessment of type 1 diabetes in relatives. Diabetes Care 1998, 21:1445–1450.

14. Sinner LR, Lin JP, Plotz PH, et al.: Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis Rheum 1998, 41:400–405.

15. Lin JP, Cash JM, Doyle SZ, et al.: Familial clustering of rheumatoid arthritis with other autoimmune diseases. Hum Genet 1998, 103:475–482.

16. Becker KG, Simon RM, Bailey-Wilson JE, et al.: Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A 1998, 95:9979–9984.

17. Wright AF, Carothers AD, Pirastu M: Population choice in mapping genes for complex diseases. Nat Genet 1999, 23:397–404.

18. Bidwell J, Kean L, Gallagher G, et al.: Cytokine gene polymorphism in human disease: on-line database. Genes Immun 1999, 1:3–19.

19. Gesnner JE, Heiken H, Tamm A, et al.: The IgG Fc receptor family. Ann Hematol 1998, 76:231–248.

20. Kook CC, Croager EJ, Witt CS, et al.: Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex. Immunogenetics 1999, 49:508–516.

This paper assesses the association of IIM with HLA DR3 in light of the extended ancestral haplotype in which DRG is found. This study suggests that the disease susceptibility gene(s) are located between the HLA DR and C4 loci, where heat shock protein and tumor necrosis factor genes are located.

21. Glass DN, Giannini EH: Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum 1999, 42:2261–2268.

This is an excellent and comprehensive review of the literature on the genetics of JRA. Though sporadic JRA is the most common rheumatic condition in children, familial JRA is much rarer because many genetic factors must work together in the pathogenesis of this disease. The MHC and non-MHC genetic loci associated with JRA are reviewed.

22. Unverricht H: Polymyositis acuta progressiva. Z Klin Med 1887, 12:533.

23. Wedgewood RPJ, Cook CD, Cohen J: Dermatomyositis: report of 26 cases in children with a discussion of endocrine therapy in 13. Pediatrics 1953, 12:447–466.

24. Maurer I, Zierz S: Recurrent orbital myositis: report of a familial incidence. Arch Neurol 1999, 56:1407–1409.

25. Plamondon S, Dent PB, Reed AM: Familial dermomyositis. J Rheumatol 1999, 26:2691–2692.

26. Garcia-De IT, I, Ramirez-Casillas A, Hernandez-Vazquez L: Acute familial myositis with a common autoimmune response. Arthritis Rheum 1991, 34:744–750.

27. Neville HE, Baumbach LL, Ringel SP, et al.: Familial inclusion body myositis: evidence for autosomal dominant inheritance. Neurology 1992, 42:897–902.

28. Love LA, Weiner SR, Vassey FB, et al.: Clinical and immunogenetic features of woman who develop myositis after silicone implants [abstract]. Arthritis Rheum 1992, 35:S46.

29. Pachman LM, Hayford Jr, Hochberg MC, et al.: New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis Rheum 1997, 40:1526–1533.

30. Friedman JM, Pachman LM, Maryjowski ML, et al.: Immunogenetic studies of juvenile dermatomyositis: HLA antigens in patients and their families. Tissue Antigens 1983, 21:45–49.

31. Reed AM, Pachman L, Ober C: Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1*0501. Hum Immunol 1991, 32:235–240.

32. Arnett FC, Targoff IN, Mimori T, et al.: Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996, 39:1507–1518.

33. Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360–374.

34. West JE, Reed AM: Analysis of HLA-DM polymorphism in juvenile dermato-myositis (JDM) patients. Hum Immunol 1999, 60:255–268.

It is known that HLA DRB1*0301 and DQA1*0501 is associated with myositis in children. However, this study describes new HLA class II loci associated with JDM. HLA DQA*0103 and DMB*0102 were risk factors for JDM in white patients. No linkage disequilibrium was noted between DRB1*0301 and the DM alleles, suggesting that DMA and DMB alleles may be involved in the pathogenesis of IM in children.

35. Reed AM, Stirling JD: Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol 1995, 44:131–135.

36. Mierau R, Dick T, Bartz-Bazzanella P, et al.: Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan position 9 of the HLA-DR beta chain. Arthritis Rheum 1996, 38:886–876.

37. Halla JT, Fällahi S, Koopman WJ: Penicillamine-induced myositis: observations and unique features in two patients and review of the literature. Am J Med 1984, 77:719–722.

38. Taneja V, Mehra N, Singh YN, et al.: HLA-D region genes and susceptibility to D-penicillamine-induced myositis. Arthritis Rheum 1990, 33:1445–1447.
490 Myositis and myopathies

39 Lehnebecher T, Foster CB, Zhu S, et al.: Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999, 94:4220–4232.

40 Kay RA: TCR gene polymorphism and autoimmune diseases. Eur J Immunogenetics 1998, 161–177.

41 Gugoujon JA, Cambon-Thomsen A: Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Autoimmunity 1995, 22:245–260.

42 Arend WP, Malayk M, Guthridge CJ, et al.: Interleukin-1 receptor antagonist: role in biology. Ann Rev Immunol 1999, 16:27–55.

43 Wilson AG, Di Giovinne FS, Duft GW: Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. J Inflammation 1995, 45:1–12.

44 Rider LG, Artlett CM, Foster CB, et al.: Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunology 2000, 120:1–7.

This paper is the first study to identify non-HLA genetic polymorphisms, in this case those encoding IL-1, an important mediator of the pro-inflammatory response, to be risk factors for juvenile IIM (JIMI). IL-1RN A1 allele was found to be a risk factor for white patients but not for black, in whom IL-1 RN A3 was a possible risk factor. This study emphasizes the ethnic variations in the genetic predispositions of myositis and also stresses the importance of non-HLA genes in the pathogenesis of IIM.

45 Rider L, Pandey J, Sherry D, et al.: Polymorphisms in cytokine genes are associated with juvenile idiopathic inflammatory myopathy (JIMI). Arthritis Rheum 1995, 39 (suppl): No 981 [abstract].

46 McGuire W, Hill AV, Alsopp CE, et al.: Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994, 371:508–510.

47 Wilson AG, Gordon C, Di Giovinne FS, et al.: A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994, 24:191–195.

48 Pachman L, Lingen M, Caliendo J, et al.: Muscle biopsy finding in 38 untreated children with juvenile dermatomyositis (JDM): capillary occlusion is associated with the TNF 2 allele [abstract]. Arthritis Rheum 1999, 42:S403.

49 Pachman LM, Liotta-Davis M, Hong D, et al.: TNF-alpha-308A allele in juvenile dermatomyositis: associations with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000, in press.

This paper looks at the possible associations of TNF alpha polymorphism at nucleotide position–308 in 37 white juvenile DM subjects. Patients with juvenile DM had a higher frequency of TNF -308A compared with normal populations. Those patients with TNF -308A had a longer disease course, as well as pathologic calcification.

50 Garlepp MJ, Lang B, Zilko PJ, et al.: HLA associations with inclusion body myositis. Clin Exp Immunol 1994, 96:40–45.

51 Askanas V, Blak M, Engel WK, et al.: Pricn protein is abnormally accumulated in inclusion-body myositis. Neuroreport 1993, 5:25–28.

52 Lamp J, Kitzler H, Walter MC, et al.: Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis. Lancet 1999, 353:465–466.

An article presenting preliminary data that methionine homozygosity at Codon 129 of the prion gene is associated not only with IBM, but also with Creutzfeldt-Jakob disease. It is interesting that both of these diseases have similar intracellular inclusions. Of note is that overexpression of the prion gene leads to degenerative muscle disorder in transgenic mice also.

53 Westaway D, Dearmond SJ, Cayetano-Canlas J, et al.: Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cell 1994, 78:117–129.

54 Askanas V, Mirabella M, Engel WK, et al.: Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases. Lancet 1994, 343:364–365.

55 Garlepp MJ, Tabarias H, Van Bockxmeer FM, et al.: Apolipoprotein E polymorphism in inclusion body myositis. Ann Neurol 1995, 38:957–959.

56 Foster CB, Lehnebecher T, Mol F, et al.: Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998, 102:2146–2155.

57 Pachman L, Hong D, Liotta M, et al.: The TNFα2 allele (AA, GA) is associated with calcinosis, a chronic disease course, and increased in vitro production of TNF-alpha but not TGF-beta by peripheral blood mononu- clear cells (PBMCs) from children with juvenile dermatomyositis [abstract]. Arthritis Rheum 1998, 41:S222.

58 Yang Q, Khoury MJ: Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research. Epidemiol Rev 1997, 19:33–43.

59 Ellsworth DL, Manolio TA: The emerging importance of genetics in epidemiologic research. I. Basic concepts in human genetics and laboratory technology. Ann Epidemiol 1999, 9:1–16.

60 Ellsworth DL, Manolio TA: The emerging importance of genetics in epidemiologic research II. Issues in study design and gene mapping. Ann Epidemiol 1999, 9:75–90.

61 Ellsworth DL, Manolio TA: The emerging importance of genetics in epidemiologic research III. Bioinformatics and statistical genetic methods. Ann Epidemiol 1999, 9:207–224.

62 Sun F, Flanders WD, Yang Q, et al.: Transmission disequilibrium test (TDT) when only one parent is available: the 1-TDT. Am J Epidemiol 1999, 150:97–104.

63 Kaprio J: Genetic epidemiology. BMJ 2000, 320:1257–1259.

64 Jaworski SL, Slater JD, Severini A, et al.: Unusual clustering of diseases in a Canadian Old Colony (Chortitza) Mennonite kindred and community. CMAJ 1988, 138:1017–1025.

65 Lawrence JS: Rheumatoid arthritis: nature or nurture? Ann Rheum Dis 1970, 29:357–379.

66 Kyyk KO, Green A, Beck-Nielsen H: Concordance rates of insulin dependent diabetes mellitus: a population-based study of young Danish twins. BMJ 1995, 311:913–917.

67 Silman AJ, Macgregor AJ, Thomson W, et al.: Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993, 32:903–907.

68 Kalman B, Lublin FD: The genetics of multiple sclerosis: a review. Biomed Pharmacother 1995, 53:358–370.

69 Todd JA: From genome to aetiology in a multifactorial disease, type 1 diabetes. Bioessays 1999, 21:164–174.

70 D’Alfonso S, Rampi M, Bocchio D, et al.: Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum 2000, 43:120–128.

71 McCurdy D: Genetic susceptibility to the connective tissue diseases. Curr Opin Rheumatol 1999, 11:399–407.

72 Winkler K: Uber die Dermatomyositis. Z. Haut Geschlechtskr 1956, 19:296–300.

73 Lambie JA, Duff IF: Familial occurrence of dermatomyositis case reports and a family survey. Ann Intern Med 1963, 59:839–847.

74 Hennekam RC, Hiemstra I, Jennekens FG, et al.: Juvenile dermatomyositis in first cousins [letter]. N Engl J Med 1990, 323:195.

75 Harati Y, Niakan E, Bergman EW: Childhood dermatomyositis in monzygotic twins. Neurology 1986, 36:721–723.

76 Massa R, Weiler B, Karpati G, et al.: Familial inclusion body myositis among Kurdish-Iranian Jews. Arch Neurol 1991, 48:819–847.

77 Moulds JM, Rolih C, Goldstein R, et al.: C4 null genes in American whites and blacks with myositis. J Rheumatol 1990, 17:331–334.

78 Hirsch T, Enlow RW, Bias WB, et al.: HLA-D related (DR) antigens in various kinds of myositis. Hum Immunol 1981, 3:181–186.

79 Koffman BM, Svavukar K, Simonis T, et al.: HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1998, 84:139–142.

80 Reed AM, Pachman LM, Hayford J, et al.: Immunogenetic studies in families of children with juvenile dermatomyositis. J Rheumatol 1998, 25:1000–1002.

81 Friedman JM, Pachman LM, Maryjowski ML, et al.: Immunogenetic studies of juvenile dermatomyositis: HLA-DR antigen frequencies. Arthritis Rheum 1983, 26:214–216.

82 Robb SA, Fielder AHL, Saunders CE, et al.: C4 Complement allotypes in juvenile dermatomyositis. Hum Immunol 1988, 22:31–38.

83 Arnett FC, Hirsch TJ, Bias WB, et al.: The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol 1981, 8:925–930.
Marguerie C, Bunn CC, Copier J, et al.: The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992, 71:327–336.

Oddis CV, Okano Y, Rudert WA, et al.: Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations. Arthritis Rheum 1992, 35:1211–1217.

Yaneva M, Arnett FC: Antibodies against Ku protein in sera from patients with autoimmune diseases. Clin Exp Immunol 1989, 76:366–372.

Askanas V, Engel WK: Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain: recent approaches to diagnosis and pathogenesis, and relation to aging. Scand J Rheumatol 1998, 27:389–405.